{"pmid":32057209,"title":"[Pharmacotherapeutics for the New Coronavirus Pneumonia].","text":["[Pharmacotherapeutics for the New Coronavirus Pneumonia].","The New Coronavirus Pneumonia (NCP, also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new Coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new Coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and Interferon-alpha is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg.kg(-1).d(-1), 3~5d ) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.","Zhonghua Jie He He Hu Xi Za Zhi","Du, B","Qiu, H B","Zhan, X","Wang, Y S","Kang, H Y J","Li, X Y","Wang, F","Sun, B","Tong, Z H","32057209"],"abstract":["The New Coronavirus Pneumonia (NCP, also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new Coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new Coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and Interferon-alpha is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg.kg(-1).d(-1), 3~5d ) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Du, B","Qiu, H B","Zhan, X","Wang, Y S","Kang, H Y J","Li, X Y","Wang, F","Sun, B","Tong, Z H"],"date":"2020-02-15T11:00:00Z","year":2020,"_id":"32057209","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.1001-0939.2020.0012","keywords":["Antibiotics","Glucocorticosteroid","New coronavirus pneumonia","Pharmacotherapeutics"],"source":"PubMed","locations":["Interferon-alpha","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647284527104,"score":6.7365713,"similar":[{"pmid":32033513,"title":"[Interpretation of \"Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5)\"].","text":["[Interpretation of \"Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5)\"].","the National Health Commission of the People's Republic of China publish the guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection (trial version 5) .With the awareness and understanding of the disease, the guidelines have been revised for recognize, treat, and prevent diseases. Then, what are the contents of the fifth edition of the guide issued updated compared to the fourth edition, now, learn together.","Zhonghua Yi Xue Za Zhi","Lin, L","Li, T S","32033513"],"abstract":["the National Health Commission of the People's Republic of China publish the guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection (trial version 5) .With the awareness and understanding of the disease, the guidelines have been revised for recognize, treat, and prevent diseases. Then, what are the contents of the fifth edition of the guide issued updated compared to the fourth edition, now, learn together."],"journal":"Zhonghua Yi Xue Za Zhi","authors":["Lin, L","Li, T S"],"date":"2020-02-09T11:00:00Z","year":2020,"_id":"32033513","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.0376-2491.2020.0001","keywords":["2019 Novel coronavirus","guidelines","pneumonia"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647055937536,"score":208.9636},{"pmid":32098466,"title":"[What are the highlights of \"Diagnosis and treatment of Disease 2019 novel coronavirus infection suitable for Military support Hubei medical team\"].","text":["[What are the highlights of \"Diagnosis and treatment of Disease 2019 novel coronavirus infection suitable for Military support Hubei medical team\"].","Thousands of medical workers in the Military support Hubei medical team are exerting themselves in many hospitals in Hubei Province. They are diligent in treating patients, at the same time, they constantly summarize experience and combine the characteristics of military hospitals. According to \" the Diagnosis and Treatment of New Coronavirus Pneumonia \"(6th edition) of the National Health Commission of the People's Republic of China, a new guideline for the diagnosis and treatment of 2019 novel coronavirus infection suitable for the military (first trial version) was established. Some unique opinions and suggestions are put forward in terms of disease name, diagnosis criteria, antiviral treatment, glucocorticoid application, etc. This article will make a proper interpretation in order to understand the guideline better and help guide the diagnosis and treatment of diseases.","Zhonghua Jie He He Hu Xi Za Zhi","Shi, Y","32098466"],"abstract":["Thousands of medical workers in the Military support Hubei medical team are exerting themselves in many hospitals in Hubei Province. They are diligent in treating patients, at the same time, they constantly summarize experience and combine the characteristics of military hospitals. According to \" the Diagnosis and Treatment of New Coronavirus Pneumonia \"(6th edition) of the National Health Commission of the People's Republic of China, a new guideline for the diagnosis and treatment of 2019 novel coronavirus infection suitable for the military (first trial version) was established. Some unique opinions and suggestions are put forward in terms of disease name, diagnosis criteria, antiviral treatment, glucocorticoid application, etc. This article will make a proper interpretation in order to understand the guideline better and help guide the diagnosis and treatment of diseases."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Shi, Y"],"date":"2020-02-27T11:00:00Z","year":2020,"_id":"32098466","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112147-20200225-00183","keywords":["Military","diagnosis and treatment","infection","medical team","novel coronavirus"],"source":"PubMed","locations":["Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647462785024,"score":193.53217},{"pmid":32023685,"title":"[Potential antiviral therapeutics for 2019 Novel Coronavirus].","text":["[Potential antiviral therapeutics for 2019 Novel Coronavirus].","The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-beta, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.","Zhonghua Jie He He Hu Xi Za Zhi","Li, H","Wang, Y M","Xu, J Y","Cao, B","32023685"],"abstract":["The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-beta, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Li, H","Wang, Y M","Xu, J Y","Cao, B"],"date":"2020-02-06T11:00:00Z","year":2020,"_id":"32023685","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.1001-0939.2020.0002","keywords":["2019 novel coronavirus","Antiviral therapy","Infection"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["General Info"],"weight":1,"_version_":1661359647155552256,"score":181.63309},{"pmid":32111114,"title":"[Recommendations for the regulation of medical practices of burn treatment during the outbreak of the coronavirus disease 2019].","text":["[Recommendations for the regulation of medical practices of burn treatment during the outbreak of the coronavirus disease 2019].","2019 novel coronavirus (2019-nCoV) is one of the beta coronaviruses and was identified as the pathogen of the severe \"coronavirus disease 2019 (COVID-19)\" in 2019. China has formally included the 2019-nCoV in the statutory notification and control system for infectious diseases according to the Law of the People's Republic of China on the Prevention and Treatment of Infectious Diseases. Currently, the national defending actions on the 2019-nCoV in China is in a critical period. Burn Department is also confronted with risk of infection by the 2019-nCoV. According to the guidelines on the diagnosis and treatment of COVID-19 (6(th) trial edition), the latest relative literature at home and abroad, the features of the COVID-19, recommendations for the COVID-19 prevention and control issued by the National Health Commission of China, and management experience of diagnosis and treatment in the related disciplines, we put forward recommendations for the medical practices of burn treatment during the outbreak of the COVID-19 in outpatient and emergency treatment, inpatient treatment, operation and ward management, etc. We hope these recommendations could benefit the professionals of the same occupation as us and related hospital managers, improve the treatment of burn during the outbreak of the COVID-19, and avoid or reduce the risk of infection of medical staff .","Zhonghua Shao Shang Za Zhi","Ma, S Y","Yuan, Z Q","Peng, Y Z","Luo, Q Z","Song, H P","Xiang, F","Tan, J L","Zhou, J Y","Li, N","Hu, G Z","Luo, G X","32111114"],"abstract":["2019 novel coronavirus (2019-nCoV) is one of the beta coronaviruses and was identified as the pathogen of the severe \"coronavirus disease 2019 (COVID-19)\" in 2019. China has formally included the 2019-nCoV in the statutory notification and control system for infectious diseases according to the Law of the People's Republic of China on the Prevention and Treatment of Infectious Diseases. Currently, the national defending actions on the 2019-nCoV in China is in a critical period. Burn Department is also confronted with risk of infection by the 2019-nCoV. According to the guidelines on the diagnosis and treatment of COVID-19 (6(th) trial edition), the latest relative literature at home and abroad, the features of the COVID-19, recommendations for the COVID-19 prevention and control issued by the National Health Commission of China, and management experience of diagnosis and treatment in the related disciplines, we put forward recommendations for the medical practices of burn treatment during the outbreak of the COVID-19 in outpatient and emergency treatment, inpatient treatment, operation and ward management, etc. We hope these recommendations could benefit the professionals of the same occupation as us and related hospital managers, improve the treatment of burn during the outbreak of the COVID-19, and avoid or reduce the risk of infection of medical staff ."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Ma, S Y","Yuan, Z Q","Peng, Y Z","Luo, Q Z","Song, H P","Xiang, F","Tan, J L","Zhou, J Y","Li, N","Hu, G Z","Luo, G X"],"date":"2020-03-01T11:00:00Z","year":2020,"_id":"32111114","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn501120-20200224-00083","keywords":["Burns","Coronavirus disease 2019","Epidemic prevention and control","Recommendations for diagnosis and treatment"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647960858624,"score":179.6048},{"pmid":32164424,"title":"COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.","text":["COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.","As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7-10% and median time to intensive care admission is 9.5-10.5 days with mortality of around 1-2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19.","Am J Chin Med","Chan, Kam Wa","Wong, Vivian Taam","Tang, Sydney Chi Wai","32164424"],"abstract":["As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7-10% and median time to intensive care admission is 9.5-10.5 days with mortality of around 1-2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19."],"journal":"Am J Chin Med","authors":["Chan, Kam Wa","Wong, Vivian Taam","Tang, Sydney Chi Wai"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32164424","week":"202011|Mar 09 - Mar 15","doi":"10.1142/S0192415X20500378","keywords":["2019-nCoV","COVID-19","Chinese Medicine","Guideline","Integrative Medicine","Review"],"source":"PubMed","locations":["Chinese","H1N1","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647946178560,"score":177.08044}]}